-
Novartis Pharmaceuticals Corporation et al v. Par Pharmaceutical Inc. DC CAFC
- 1:14-cv-01494
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/18/2014
- Closed: 05/01/2019
- Latest Docket Entry: 05/02/2019
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
1
Accused
Product
3
Patents-in-Suit
1,596
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. Par Pharmaceutical Inc. DC CAFC
- 1:14-cv-01494
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/18/2014
- Closed: 05/01/2019
- Latest Docket Entry: 05/02/2019
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A compound of the formula ##STR3## wherein R.sup.1 is hydroxy(C.sub.1-6)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.
|
Enforceable and Valid
Entry 128 |
2 |
A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.
|
Enforceable and Valid
Entry 128 |
3 |
A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl.
|
Enforceable and Valid
Entry 128 |
10 |
The compound according to claim 1 which is 40-O-(3-hydroxyethyl)-rapamycin.
|
Enforceable and Valid
Entry 128 |
All Claims |
NA
|
Invalid (101 and 103)
Entry 107 |
-
Infringement
Par Pharmaceutical, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg dosage strength, Everolimus tablets | US 5,665,772 A |
1, 2, 3, 10
|
Infringement
Entry 128
|